NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading TSHA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Advance TSHA-102 clinical development on schedule: TSHA-102 development advances as planned (shortened timeline positively impacts TSHA-102 development).
View ThesisRevenue is growing steadily — about 3% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 33%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 3% on a typical day and fell roughly 31% in its worst 12-month stretch.
View RiskTSHA's growth in clinical development for TSHA-102 is crucial for its valuation. The company is advancing TSHA-102 on schedule, which is a positive sign. It trades at 288× price-to-sales, while the peer median is 9×. This suggests the price is roughly in line with expected growth. If TSHA cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 33% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. TSHA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering TSHA (as of Jul 2026).
Based on 3 Wall Street analysts offering 12-month price targets for TSHA in the last 4 months.
A consensus fair price across our valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No fair value published
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
This applies to all three horizons. The trailing multiples, peer comparison, and quality and trajectory reads on this page are unaffected. Names move in and out of this state day to day as the methods converge or diverge. Method agreement on this name is low.
Bottom 25% on quality vs scored peers
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Advances: Advance TSHA-102 clinical development
Shortened timeline positively impacts TSHA-102 development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $5.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $5.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
